# US 2022/0016234 A1 · Anti covid-19 therapies using nucleocapsid and spike proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016234 A1
- Document ID: US20220016234A1
- Status: Published application
- Kind: A1
- Application number: 17/405,393
- Filed: 2021-08-18
- Published: 2022-01-20
- Earliest claimed: 2020-03-11
- Assignees: ImmunityBio, Inc.
- Applicants: ImmunityBio, Inc.
- Inventors: Adrian Rice; Mohit Verma
- Web page: https://patentgrep.com/patent/US20220016234A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- C07K 14/8103: {Exopeptidase (E.C. 3.4.11-19) inhibitors}
- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- C07K 14/165: Coronaviridae, e.g. avian infectious bronchitis virus
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/235: Adenoviridae
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 1/16: Yeasts; Culture media therefor
- C12N 2710/10341: Use of virus, viral particle or viral elements as a vector
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20071: Demonstrated in vivo effect
- C12N 2770/36122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/36134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12Y 304/17023: Angiotensin-converting enzyme 2 (3.4.17.23)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), followed by administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion.

## Claims

### Claim 1

A method of inducing immunity against an antigen in a patient, the method comprising:
administering a vaccine composition comprising a self-adjuvanted RNA-based vaccine, wherein the RNA encodes the antigen; and
administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion, and wherein the hAd5 comprises a nucleotide encoding the antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antigen is a severe acute respiratory syndrome type II coronavirus (SARS-CoV2) S protein and/or a SARS-CoV2 Nucleocapsid (N) protein.

### Claim 3 (depends on 2)

The method of claim 2, wherein the SARS-CoV2 S protein further comprises a fusion motif to increase cell-surface expression and a diproline (pp) to stabilize S.

### Claim 4 (depends on 2)

The method of claim 2, wherein the SARS-CoV2 N protein further comprises an Enhanced T-cell Stimulation Domain (N-ETSD) to direct N to the endosomal/lysosomal compartment.

### Claim 5 (depends on 1)

The method of claim 1, wherein the RNA-based vaccine composition comprises a self-adjuvanted RNA replicon construct encoding the SARS-CoV-2 S protein.

### Claim 6 (depends on 5)

The method of claim 5, wherein the RNA-based vaccine composition further comprises non-structural proteins 1-4 derived from the Venezuelan equine encephalitis virus (VEEV) vaccine.

### Claim 7 (depends on 1)

The method of claim 1, wherein the RNA-based vaccine composition is delivered to the patient by intramuscular (IM) injection, intravenous (IV) injection, and/or subcutaneous injection.

### Claim 8 (depends on 7)

The method of claim 7, wherein the RNA-based vaccine composition comprises a lipid nanoparticle encasing coronaviral mRNA.

### Claim 9 (depends on 1)

The method of claim 1, wherein the hAd5 vaccine composition is delivered to the nasal mucosa, oral mucosa, and/or alimentary mucosa of the patient.

### Claim 10 (depends on 1)

The method of claim 1, wherein the hAd5 vaccine composition is delivered by subcutaneous injection.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hAd5 vaccine composition is administered orally after the RNA-based vaccine injection.

### Claim 12 (depends on 11)

The method of claim 11, wherein the hAd5 vaccine composition comprises aragonite particle beads.

### Claim 13 (depends on 1)

The method of claim 1, wherein the hAd5 vaccine composition is administered as a booster immunization at least one week after the RNA-based vaccine injection.

### Claim 14 (depends on 13)

The method of claim 13, wherein the hAd5 vaccine composition is administered at least two weeks after the RNA-based vaccine injection.

### Claim 15 (depends on 1)

The method of claim 1, wherein the hAd5 further comprises an E3 gene region deletion and/or an E4 gene region deletion.

### Claim 16 (depends on 1)

The method of claim 1, further comprising analyzing a sample of saliva from the patient for antibodies targeting the SARS-CoV2 and/or for a protein specific to the SARS-CoV2.

### Claim 17 (depends on 16)

The method of claim 16, further comprising administering a second dose of the hAd5 vaccine to the patient.

### Claim 18 (depends on 1)

The method of claim 1, wherein the hAd5 vaccine composition comprises a nucleotide encoding a polypeptide with at least 90% sequence identity to SEQ ID NO:10.

### Claim 19 (depends on 1)

The method of claim 1, wherein the hAd5 vaccine composition comprises a nucleotide encoding a polypeptide with at least 90% sequence identity to SEQ ID NO:12.

### Claim 20 (depends on 1)

The method of claim 1, wherein the hAd5 vaccine composition comprises the nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13 or SEQ ID NO:14.
